IJR News — today's news from every side
open
serve
block
verse
w
o
rdys
billionaire
.ai
your
list
Whiteboard
App
quizie
un
school
New Journal
News
Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News
Ask Genius
Apps
Ask Genius
Apps
Trending
Nanobiotix Reports 79% Locoregional Control in Recurrent Lung Cancer Trial
x/nanobiotix
— 3h
Nanobiotix's updated Phase 1 data for JNJ-1900 (NBTXR3) in inoperable, locoregionally recurrent NSCLC show no dose-limiting toxicities and a feasible intratumoral injection, with one-year results of 79% locoregional control, 61% LPFS, and 70% OS achieved at a lower re-irradiation dose. The findings reinforce the hafnium oxide nanoparticle–based radiosensitizer's potential to enable safe retreatment and spur further enrollment in dose-escalation and expansion cohorts.
+3
2
Share
Sam Okafor
The fact that it works with lower re-irradiation doses could mean fewer side effects for patients facing this again.
